Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Carcinoma, Non-Small-Cell Lung × Nivolumab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 119 OTHER 110 OTHER_GOV 5 NIH 4 NETWORK 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrent Squamous Cell Lung Carcinoma 2 Melanoma 2 Hodgkin Disease 2 Thymoma 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Inoperable œsophageal Cancer 1 Gastric and Esophagogastric Junction Adenocarcinoma 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Brain Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Carboplatin 33 Paclitaxel 28 Radiotherapy 23 Cisplatin 23 Docetaxel 18 Gemcitabine 14 Pemetrexed 13 Radiosurgery 9 Bevacizumab 9 Magnetic Resonance Spectroscopy 7 Etoposide 7 Ramucirumab 6 Erlotinib Hydrochloride 6 Cetuximab 6 Specimen Handling 5 Gene Expression Profiling 5 durvalumab 4 cediranib 4 Vinorelbine 4 Polymerase Chain Reaction 4 Amplified Fragment Length Polymorphism Analysis 4 pembrolizumab 3 cemiplimab 3 Watchful Waiting 3 Taxes 3 Surgical Procedures, Operative 3 Radiotherapy, Conformal 3 Psychiatric Rehabilitation 3 Neoadjuvant Therapy 3 Fluorodeoxyglucose F18 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02434081 2022-08-24

NICOLAS

ETOP IBCSG Partners Foundation

Phase 2 Completed

94 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡